Saturday, 20 April 2024
Aviragen Therapeutics Inc.
NASDAQ : AVIR
5.250 14 Oct 22 00:00 | Change: 0.01 | Open: 5.300 | High: 5.490 | Ask: 0.000 | Volume: 395,800 |
Change(%): 0.19 | Prev: 5.260 | Low: 5.180 | Bid: 0.000 | Avg vol: 0 |
01:56 | 8/3/18
Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vaxart, Inc. (NASDAQ: VXRT) a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that the United States Patent and ...
more»
04:45 | 7/3/18
Benchmark Monitor
Vaxart, Inc. (NASDAQ:VXRT) announced that it had presented clinical data from two Phase 1 studies of its norovirus oral tablet vaccine at the 18th International Congress on Infectious Diseases (ICID), took place from March 1-4, 2018 in Buenos Aires ...
more»
01:56 | 3/3/18
Business Wire
“The clinical data to be presented at ICID demonstrate that our orally administered norovirus tablet vaccine was well-tolerated and generated robust systemic and local intestinal immune responses,” said Sean Tucker, Ph.
more»
09:48 | 1/3/18
Danvers Record
Shares of Vaxart Inc. (VXRT) are moving on volatility today -4.58% or $-0.27 from the open. The NASDAQ listed company saw a recent bid of $5.63 and 19417 shares have traded hands in the session.
more»
20:52 | 24/2/18
StockNewsTimes
Vaxart logo Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally.
more»
There are currently no comments on this topic.
Be the first person to Add a Comment...
You must be a registered user to post a comment: REGISTER NOW
If you are already registered, please LOGIN NOW
|
Code | Last | Change |
COMP | 10,321 | 328 | | 3.08% |
DJI | 29,635 | 404 | | 1.34% |
SP500 | 3,583 | 87 | | 2.37% |
DAX | 12,438 | 82 | | 0.67% |
FTSE | 7,488 | 5 | | 0.07% |
NI225 | 22,420 | 408 | | 1.86% |
TWI | 67.27 | 0.00 | | 0.00% |